D

Deep Blue Retina Clinical Research | Southaven, MS

Research site

(Unclaimed)

Location

7900 Airways Blvd, Building A, Suite 1, Southaven, Mississippi, United States of America

Site insights

Top conditions

Top treatments

UBX1325

BI 764524

EYP-1901

Aflibercept

Foselutoclax

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Biological: 4D-150 IVT (3E10 vg/eye)

Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Active, not recruiting

Neovascular Age-Related Macular Degeneration

Diabetic Macular Edema

Drug: Aflibercept 8 mg

Locations recently updated

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling

Diabetic Retinopathy

Drug: BI 764524

Drug: Aflibercept (Eylea®) - US only